Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/4782
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMelo, Andreia Cristina de-
dc.contributor.authorPaulino, Eduardo-
dc.contributor.authorCalabrich, Aknar Freire de Carvalho-
dc.contributor.authorGuimarães, Andréa Paiva Gadelha-
dc.contributor.authorFreitas, Daniela-
dc.contributor.authorMaluf, Fernando Cotait-
dc.contributor.authorFaroni, Lilian Dantonino-
dc.contributor.authorVieira, Marcelo de Andrade-
dc.contributor.authorRibeiro, Reitan-
dc.contributor.authorRodrigues, Angélica Nogueira-
dc.date.accessioned2021-12-15T12:06:42Z-
dc.date.available2021-12-15T12:06:42Z-
dc.date.issued2018-
dc.identifier.citationMELO, Andreia Cristina de et al. 2018 in review: gynecologic cancer insights. Braz J Oncol., p. 1-5, dec. 2018.-
dc.identifier.issn2526-8732-
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/4782-
dc.descriptionp. 1-5.: tab. p&b.-
dc.description.abstractGynecologic cancers constitute an important burden of disease around the world. Estimates from GLOBOCAN 2018 reveals approximately 1,247,300 incident casesand 596,000 related deaths of cancers of the uterine cervix, corpus uteri, and ovarian, annually around the world. In 2018 lots of promising results to improve disease control have been presented at international gynecological cancer meetings. The current review highlights some of the top gynecologic cancer news of 2018, including the new standard of care for BRCAmutant ovarian cancer patients with maintenance olaparib in first line, benefit of bevacizumab rechallenge for relapsed ovarian cancer patients, and the unexpected results of worse overall survival with minimally invasive surgery in early cervical cancer, among others.-
dc.publisherBraz J Oncol.pt_BR
dc.subjectRevisãopt_BR
dc.subjectReviewpt_BR
dc.subjectNeoplasias dos Genitais Femininospt_BR
dc.subjectGenital Neoplasms Femalept_BR
dc.title2018 in review: gynecologic cancer insightspt_BR
dc.TypeArticlept_BR
dc.description.abstractenOs tumores ginecológicos constituem um verdadeiro fardo à saúde feminina mundialmente. Estimativas do GLOBOCAN 2018 demonstram cerca de 1.247.300 casos e 596.000 mortes anualmente relacionadas aos tumores ginecológicos. Em 2018 foram apresentados trabalhos importantes sobre o manejo destes tumores nos principais congressos internacionais. Esse artigo de revisão destaca alguns destes trabalhos como a manutenção de olaparibe em primeira linha para as pacientes com câncer de ovário e mutação de BRCA, o benefício da re-exposição ao bevacizumabe para pacientes com câncer de ovário recidivado (platino sensível), os resultados inesperados da cirurgia minimamente invasiva em câncer de colo uterino inicial, dentre outros.-
Appears in Collections:Artigos de Periódicos da área de Ginecologia

Files in This Item:
File Description SizeFormat 
2018 in review gynecologic cancer insights..pdf106.96 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.